Dr. Polakit Teekakirikul, a cardiology fellow in the Heart & Vascular Institute, is lead author on an expert opinion article featured on the American College of Cardiology education website. “Mitral valve derangement is increasingly recognized as a fundamental phenotype in hypertrophic cardiomyopathy,” said Dr. Teekakirikul, “which must be considered as part of evaluation for any type of invasive therapy to treat outflow tract obstruction.” He and senior author, Dr. Timothy Wong, discussed a pragmatic approach to the evaluation of hypertrophic cardiomyopathy (HCM) patients and provided sample imaging data from patients enrolled in a research registry at the UPMC Heart & Vascular Institute. “Hypertrophic cardiomyopathy is a rare disease involving thickening of the heart muscle for which an increasing number of medical and interventional therapies are becoming available – the UPMC HCM Center is excited to be part of such a dynamic field where we can apply cutting edge research and treatments to our patients!” said Dr. Wong.
MR in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
Polakit Teekakirikul, MD; Timothy Wong, MD